May. 8 at 3:41 PM
$PHIO — listen up, people, this is a LOTTERY TICKET, not an investment!
Tiny biotech. Cancer immunotherapy via RNA interference. Lead drug PH-762 — still in EARLY trials. No approved products. No real revenue. ZIP!
The bull case? Yeah, there is one! Early PH-762 data showed encouraging responses, safety looks acceptable, and they've got
$20M in the till — runway into 2027. Market cap is microscopic, so good news could send this thing to the MOON!
The bear case? Bleeding cash every year. Surviving on dilution and capital raises. Already did a REVERSE SPLIT in 2024 to keep its Nasdaq seat! There's no real business under the hood — the whole thing rides on the science.
Here's the deal — if PH-762 HITS, upside could be massive because the company's so tiny. If it FLOPS? More dilution, more splits, lower lows. That's the trade.
Bottom line? PHIO is a legit clinical-stage gambler's stock. NOT a stable company. Only speculate with money you can afford to lose!
